Research Analysts Set Expectations for Black Diamond Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:BDTX)

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) - Research analysts at Wedbush issued their Q1 2024 EPS estimates for shares of Black Diamond Therapeutics in a note issued to investors on Monday, April 8th. Wedbush analyst R. Driscoll anticipates that the company will post earnings of ($0.41) per share for the quarter. Wedbush has a "Outperform" rating and a $16.00 price objective on the stock. The consensus estimate for Black Diamond Therapeutics' current full-year earnings is ($1.76) per share. Wedbush also issued estimates for Black Diamond Therapeutics' Q2 2024 earnings at ($0.35) EPS, Q3 2024 earnings at ($0.36) EPS, Q4 2024 earnings at ($0.38) EPS, FY2024 earnings at ($1.49) EPS, FY2025 earnings at ($1.58) EPS, FY2026 earnings at ($1.65) EPS, FY2027 earnings at ($1.64) EPS and FY2028 earnings at $1.10 EPS.

Black Diamond Therapeutics (NASDAQ:BDTX - Get Free Report) last issued its quarterly earnings results on Tuesday, March 12th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.13.

Separately, HC Wainwright reaffirmed a "buy" rating and set a $12.00 price objective (up previously from $11.00) on shares of Black Diamond Therapeutics in a research report on Monday, March 18th.

Black Diamond Therapeutics Stock Up 11.8 %

Shares of NASDAQ:BDTX traded up $0.59 during trading on Thursday, reaching $5.57. 571,908 shares of the company traded hands, compared to its average volume of 576,934. The firm has a market capitalization of $288.07 million, a PE ratio of -2.96 and a beta of 2.64. Black Diamond Therapeutics has a 52 week low of $1.43 and a 52 week high of $6.85. The company's 50 day moving average is $4.74 and its two-hundred day moving average is $3.31.

Hedge Funds Weigh In On Black Diamond Therapeutics

A number of institutional investors have recently modified their holdings of BDTX. Point72 Asset Management L.P. acquired a new position in Black Diamond Therapeutics during the second quarter worth about $10,100,000. JPMorgan Chase & Co. grew its holdings in shares of Black Diamond Therapeutics by 195,562.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,080,059 shares of the company's stock valued at $5,454,000 after purchasing an additional 1,079,507 shares during the last quarter. Kennedy Capital Management LLC acquired a new position in Black Diamond Therapeutics during the 2nd quarter worth approximately $3,795,000. BlackRock Inc. lifted its stake in Black Diamond Therapeutics by 99.0% in the 2nd quarter. BlackRock Inc. now owns 1,505,439 shares of the company's stock valued at $7,602,000 after purchasing an additional 749,052 shares during the last quarter. Finally, Blue Owl Capital Holdings LP bought a new position in shares of Black Diamond Therapeutics in the 4th quarter valued at $1,953,000. Institutional investors and hedge funds own 95.47% of the company's stock.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc, a clinical-stage precision oncology medicine company, focuses on the discovery and development of therapies for patients with genetically defined cancers. The company's lead product candidate, BDTX-1535, a brain-penetrant, mutant selective, irreversible EGFR MasterKey inhibitor, designed to inhibit a family of oncogenic mutations, currently under Phase 1 clinical trial.